A Phase III Study of SKB264 for EGFR Mutant NSCLC Patients
Clinical trial NCT05870319 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05870319
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2023-06-26
- Primary completion
- 2024-07-11
- Enrollment
- 376
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.